Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease
Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Chenglong Han(Janssen (United States)), Julián Panés(Hospital Clínic de Barcelona), Brian G. Feagan(Western University), Susan D. Mathias(Health Outcomes Solutions (United States)), Kuan‐Hsiang Gary Huang(Janssen (United States)), Natalie A. Terry(Janssen (United States)), Hongyan Zhang(Tianjin University), Aparna Sahoo(Otsuka (United States)), Marion Vetter(Janssen (United States)), Jewel Johanns(Johnson & Johnson (United States)), Matthew Germinaro(Johnson & Johnson (United States))
Cited by 10
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k